Alnylam Pharmaceuticals this week provided an update to its research and development activities, adding a new preclinical program to its pipeline with ALN-AS1 for acute intermittent porphyria while dropping its refractory anemia drug ALN-HPN in order to focus on “higher priority” efforts.

Notably, the ALN-AS1 program will take advantage of Alnylam's GalNAc conjugate liver-delivery strategy, reflecting the company's growing focus on conjugates, which CEO John Maraganore described in 2011 as “the future for delivery of small interfering RNAs.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.

A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.

The New York Times writes about the appearance of mosaicism in healthy people.

In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.

Jun
19
Sponsored by
ACD

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.